For patients with wet AMD¹

THEIR VISION IS A MASTERPIECE

NOW APPROVED

In two head-to-head trials vs aflibercept, Beovu^®1:

• Demonstrated robust vision gains²*

• Outperformed aflibercept in achieving superior fluid resolution^1,2†

• Maintained a majority of patients on a q12w interval immediately after loading through Week 48¹

AMD=age-related macular degeneration; BCVA=best corrected visual acuity; ETDRS=early treatment diabetic retinopathy study; q12w=treatment every 12 weeks.

*The primary efficacy endpoint for the studies was the change from baseline in BCVA at Week 48 as measured by the ETDRS Letter Score, with the primary objective to demonstrate noninferiority of Beovu vs aflibercept.
^†Secondary endpoint in HAWK and HARRIER, confirmatory analysis in HAWK only (1-sided P values for superiority of Beovu).

REFERENCES

1. Summary of Product Characteristics. Novartis; 2020.

2. Dugel PU, Koh A, Ogura Y, et al; on behalf of the HAWK and HARRIER Study Investigators. HAWK and HARRIER: Phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration. Ophthalmology. 2020;127(1):72-123.

Beovu^® SmPC